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1Implementing the State’s
Comprehensive Cancer Control Plan
2004 CANCER IN IOWA REPORT
STATE HEALTH REGISTRY OF IOWA
2In 2004, an estimated 6,500 Iowans will die from cancer, 13 times the
number caused by auto fatalities. Cancer is second only to heart disease
as a cause of death. These projections are based upon mortality data the
State Health Registry of Iowa receives from the Iowa Department of Public
Health. The Registry has been recording the occurrence of cancer
in Iowa since 1973, and is one of fourteen registries nationwide providing
data to the National Cancer Institute. With the 2004 Cancer in Iowa Report
the Registry makes a general report to the public on the status of cancer.
 This report will focus on:
• a description of the Registry and its goals;
• cancer estimates for 2004;
• a special section on comprehensive cancer control in the state of Iowa;
• brief summaries of research projects during 2004;
• a selected list of publications from 2003.
3THE STATE HEALTH REGIS TRY OF IOWA
Cancer is a reportable disease as stated in the Iowa Administrative Code. Cancer data are collected by the State Health
Registry of Iowa, located at The University of Iowa in the College of Public Health’s Department of Epidemiology.
The staff includes more than 50 people. Half of them, situated throughout the state, regularly visit hospitals, clinics,
and medical laboratories in Iowa and neighboring states to collect cancer data. In 2004 data will be collected on an
estimated 15,200 new cancers among Iowa residents. A follow-up program tracks more than 97 percent of the cancer
survivors diagnosed since 1973. This program provides regular updates for follow-up and survival. The Registry
maintains the confidentiality of the patients, physicians, and hospitals providing data.
Since 1973 the Iowa Registry has been funded by the Surveillance, Epidemiology, and End Results (SEER) Program
of the National Cancer Institute (NCI). Iowa represents rural and midwestern populations and provides data
included in many NCI publications. Beginning in 1990 about 5-10 percent of the Registry’s annual operating budget
has been provided by the state of Iowa. Beginning in 2003, the University of Iowa is also providing cost-sharing
funds. The Registry also receives funding through grants and contracts with university, state, and national researchers
investigating cancer-related topics.
The goals of the Registry are to:
• assemble and report measurements of cancer incidence, survival and mortality among Iowans;
• provide information on changes over time in the extent of disease at diagnosis, therapy, and patient survival;
• promote and conduct studies designed to identify factors relating to cancer etiology, prevention and control;
• respond to requests from individuals and organizations in the state of Iowa for cancer data and analyses;
• provide data and expertise for cancer research activities and educational opportunities.
During 2004, the Registry will respond to 300 requests for data, analyses,
and cancer cluster investigations.
4CANCER PROJECTIONS FOR 2004
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In 2004, cancer will strike five out of every 1,000 Iowans. Cancer is the
second leading cause of death in Iowa, responsible for 230 of every 1,000 deaths.
Estimated Number of New Cancers in Iowa for 2004
Estimated Number of Cancer Deaths in Iowa for 2004
2
In every county, the number
of new cancers is much greater
than the number of cancer
deaths. This coincides with
more and more Iowans surviving
their cancer.
5New Cancers in Females
Type                # of Cancers % of Total
Breast 2250 30.0
Colon & Rectum 1100 14.7
Lung 870 11.6
Uterus 490 6.5
Non-Hodgkin’s Lymphoma 290 3.9
Skin Melanoma 280 3.7
Ovary 260 3.5
Leukemia 190 2.5
Pancreas 180 2.4
Thyroid 170 2.3
All Others 1420 18.9
Total 7500
New Cancers in Males
Type                 # of Cancers % of Total
Prostate 2200 28.6
Lung 1150 14.9
Colon & Rectum 1000 13.0
Non-Hodgkin’s Lymphoma 300 3.9
Skin Melanoma 290 3.8
Leukemia 270 3.5
Kidney & Renal Pelvis 250 3.2
Bladder 240 3.1
Pancreas 190 2.5
Oral Cavity 180 2.3
All Others 1630 21.2
Total 7700
Cancer Deaths in Females
Type                # of Cancers % of Total
Lung 690 21.9
Breast 460 14.6
Colon & Rectum 390 12.4
Ovary 190 6.0
Pancreas 190 6.0
Non-Hodgkin’s Lymphoma 150 4.8
Leukemia 130 4.1
Uterus 90 2.9
Brain 70 2.2
Multiple Myeloma 70 2.2
All Others 720 22.9
Total 3150
Cancer Deaths in Males
Type                # of Cancers % of Total
Lung 1040 31.0
Prostate 400 11.9
Colon & Rectum 350 10.4
Pancreas 170 5.1
Leukemia 160 4.8
Non-Hodgkin’s Lymphoma 150 4.5
Kidney & Renal Pelvis 120 3.6
Esophagus 120 3.6
Brain 90 2.7
Bladder 90 2.7
All Others 660 19.7
Total 3350
Fortunately for Iowans, the chances of being diagnosed with
many types of cancer can be reduced through positive health practices
such as smoking cessation, physical exercise, healthful dietary habits,
and alcohol consumption in moderation. Early detection through self-examination
and regular health checkups can improve cancer survival.
TOP 10 TYPES OF CANCER IN IOWA ES TIMATED FOR 2004
3
6COMPREHENSIVE CANCER CONTROL
Comprehensive Cancer Control (CCC), as defined by
the Centers for Disease Control and Prevention, is an
integrated and coordinated approach to reducing cancer
incidence, morbidity, and mortality through prevention,
early detection, treatment, rehabilitation, and palliation.
It improves cancer prevention and control efforts by
bringing together stakeholders who focus on improving
cancer services by:
• Enhancing infrastructure;
• Mobilizing support to maximize resources;
• Using data and research to develop sound strategies;
• Building partnerships that facilitate coordination and
collaboration of efforts;
• Addressing the cancer burden by targeting specific
needs and prioritizing activities to meet the needs; and
• Evaluating efforts.
The Burden of Cancer in Iowa
For the years 1973-2001 over 380,000 cancers have been
newly diagnosed among Iowans. More than 170,000
Iowans have died from cancer. The following map (Figure 1)
demonstrates an appreciable burden of cancer exists in every
county in Iowa.
Healthy Iowans 2010
In an effort to advance the boundaries of healthy living
and a high quality of life as well as to eliminate health
disparities in the new decade, 200 organizations developed
the document, Healthy Iowans 2010. Healthy Iowans 2010
is a statewide effort for health promotion and disease
prevention and is the state’s contribution to Healthy People
2010, the federal government’s national public health plan
coordinated by the United States Department of Health
and Human Services. The foundation for a national
prevention agenda was laid with the 1979 Surgeon
General’s Report, Healthy People. Since then, these agendas
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Figure 1. New Cancers and Cancer Deaths, 1973-2001
Total new cancers (n=382,184)
Total cancer deaths (n=173,369)
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7have called for each state to contribute ideas and initiatives
for improving the health of their citizenry.
The Healthy Iowans 2010 report came on the heels of a
“report card” issued by the Iowa Department of Public
Health on the Healthy Iowans 2000 goals. That analysis
showed that nearly 70% (93 of 134) goals set out in 1993
were achieved.
The cancer chapter in Healthy Iowans 2010 focuses on all
cancers combined as well as cancers where modifiable risk
factors have been identified and/or screening guidelines
have been widely accepted. A similar percent improvement
was used for Iowa as was specified for the United States in
Healthy People 2010. Iowa’s baseline cancer rates differ,
however, from those of the United States and therefore year
2010 goals differ. The cancer site goals for Healthy Iowans
2010 are shown in Figure 2.
Figure 2. Cancer Site Goals of Healthy Iowans 2010
5
                      Year 2010 Goal*
Goal Cancer Site# Gender         (Iowa Baseline Rate+)        Iowa      U.S.
2-1 All sites mortality M & F 21% (198.2) 157.0 159.9
2-2 All sites incidence M & F 10% (463.2) 417.0      NE
2-4 Lung M & F 22% (54.6) 42.6 44.9
2-5 Breast F 20% (29.2) 23.4 22.3
2-6 Cervix F 60% (2.6) 1.0 2.0
2-7 Colorectum M & F 34% (23.5) 15.5 13.9
2-8 Oropharynx M & F 15% (2.6) 2.2 2.7
2-9 Prostate M 10% (36.2) 32.6 28.8
2-10 Skin melanoma M & F 10% (2.6) 2.3 2.5
#  Each goal is for mortality except Goal 2-2 which is for incidence.
* Goal expressed as a rate.
+ All rates expressed per 100,000 population and age-adjusted to
Year 2000 U.S. standard; Iowa baseline rates from 1994-96.
NE=not established
Improvement
Lung, colorectum, female breast, and prostate are cancer sites specifically targeted in
Healthy Iowans 2010. These four cancer sites account for over 50% of all
newly diagnosed cancers and cancer deaths in Iowa. Improvement in all sites incidence
and mortality requires that progress be made with these major cancer sites.
8The Iowa Cancer Registry has data available to evaluate
progress toward the goals of Healthy Iowans 2010. Utilizing
data from 2000-2002 for the mortality goals (all but goal
2-2), the rate can be compared to the goal from the years
1994-1996. The goal for all sites incidence was compared
using 1994-1996 and 1999-2001, since data are not
complete yet for new cancer cases for the year 2002.
Figure 3 shows that as a state, the rates for all the goals
listed are moving in the right direction except for all sites
incidence. Mortality rates for female breast cancer and
prostate cancer for 1993-2002 are shown in Figure 4.
The 2002 mortality rate for female breast cancer is 25.2
which is approaching the 2010 goal of 23.4. The 2002
mortality rate for prostate cancer is 30.1 which already
is lower than the 2010 goal of 32.6. Furthermore, these
trends are occurring in the most common cancers
(excluding non-melanotic skin cancers) among women
and men in Iowa. A formal midcourse review of Healthy
Iowans 2010 is planned for later this year.
6
          Mortality Rates*          Trend Moving
Cancer Site Gender      1994-96   2000-2002    in Right Direction?
All sites mortality M & F 198.2 188.5 Yes
All sites incidence M & F 463.2 475.9 No
Lung M & F         54.6 51.6 Yes
Breast F         29.2 24.1 Yes
Cervix F 2.6 2.3 Yes
Colorectum M & F 23.5 21.0 Yes
Oropharynx M & F 2.6 2.2 Yes
Prostate M 36.2 29.3 Yes
Skin melanoma M & F 2.6 2.2 Yes
* Expressed per 100,000 and age-adjusted to Year 2000 U.S. standard; for all sites,
   both mortality and incidence rates  are provided.
Figure 3. Progress Towards Goals of Healthy Iowans 2010
Trend in Iowa
For more information on Healthy Iowans 2010, visit
www.idph.state.ia.us/admin/healthy_iowans_2010.asp
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Figure 4a. Mortality Rates for Female Breast Cancer,
    1993-2002
Figure 4b. Mortality Rates for Prostate Cancer,
     1993-2002
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THE FACE OF CANCER IN IOWA
In 2001, the Iowa Legislature commissioned a detailed
study of the impact of cancer on the state of Iowa.
The Iowa Cancer Registry provided data to measure the
cancer burden. The report, The Face of Cancer in Iowa, was
published in January of 2002 (http://www.idph.state.ia.us/
hppab/pdf/Cancer_full_report.pdf ). It contains recom-
mendations for developing a statewide, comprehensive
cancer prevention and control plan to reduce the burden
of cancer on Iowans by:
• Preventing cancer from ever occurring whenever possible,
• Detecting cancer in its earliest stages when it occurs,
• Treating any cancer found with the most appropriate
treatment known,
• Assuring that the quality of life of cancer patients is the
best it can be, and,
• Move research findings more quickly into prevention
and control practices.
The Face of Cancer in Iowa report, in part, led to the
formation of  the Iowa Consortium for Comprehensive
Cancer Control. The Consortium is comprised of over
100 people representing approximately 50 agencies from
across the state. It developed a state comprehensive cancer
control plan in April of 2003. This state plan was funded
in October of 2003 by the Centers for Disease Control
through an implementation grant that is providing initial
funding to address activities targeting cancer prevention,
early detection, treatment, quality of life, and research.
In addition, it includes cross-cutting issues related to
advocacy, patient education, financial issues, surveillance,
data and evaluation, population disparities, and web-based
information resources. For the current year the
Consortium, through its implementation groups and
standing committees, will focus on issues related to
tobacco, obesity, youth exposure to sun, screening barriers,
patient and family resources, genetics, data and evaluation,
and a cancer information website. For more information
about the Comprehensive Cancer Control plan, contact
Lorrie Graaf, Public Health Advisor, at 515-281-7739.
Links to resources for comprehensive cancer control
http://cancercontrolplanet.cancer.gov
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RESEARCH PROJECT S DURING 2004
The State Health Registry of Iowa is participating in over
two dozen funded studies during 2004. Brief descriptions
of a few of these studies are provided.
The Agricultural Health Study
The Agricultural Health Study is a long-term study of
agricultural exposures and chronic disease (especially
cancer) among commercial or private pesticide applicators
(and their spouses, if married) in Iowa and North Carolina.
The study is funded primarily by the National Cancer
Institute. We are in the 12th year of the study, which was
funded at the end of 2003 for continuation through 2008.
In the first five years, 89,658 subjects (58,564 in Iowa and
31,094 in North Carolina) were enrolled in the study.
This total for Iowa included 31,877 private applicators,
21,771 spouses of private applicators, and 4,916
commercial applicators. The second phase of the study for
private applicators and their spouses was completed at the
end of 2003. It involved a telephone interview, a mailed
dietary questionnaire, and collection of a cheek cell sample.
The telephone interview asked about pesticide use since
enrollment, current farming and work practices, and health
changes. The dietary health questionnaire asks about
cooking practices and types of foods eaten. Cooking
practices and diet may play a role in cancer and other health
conditions. The cheek cells will be used to understand
possible links between genetics, exposures, and disease.
The second phase of the study is ongoing with
commercial applicators.
Since 1997, cohort members have been linked annually to
mortality and cancer registry incidence databases in both
states. In addition, mortality data on the cohort is being
obtained every other year from the National Death Index.
More information about recent results from this study,
the study background, frequently asked questions, other
resources (internet & telephone) for agricultural health
information, references for publications to date, and
information for scientific collaborators can be found at
the website, www.aghealth.org.
Breast Cancer, Radiation Exposure, and
Genetic Susceptibility
The objective of this study is to investigate gene-
environment interactions in the etiology of breast cancer.
We are establishing a repository of epidemiologic risk factor
information and biologic specimens for a targeted goal
of 700 women with asynchronous bilateral breast cancer
(cases) and 1400 women with unilateral breast cancer
(controls),  who are being ascertained through 5
population-based tumor registries in the U.S. and
Denmark, including the Iowa Cancer Registry. All subjects
are being interviewed using a structured questionnaire and
blood samples are being collected for genetic analyses.
Initially, we will examine the interaction of radiation
exposure, the ataxia-telangiectasia mutated (ATM) gene,
and breast cancer. Ionizing radiation is known to be a breast
carcinogen and recent studies suggest that the ATM gene
may increase susceptibility to radiation-induced breast
cancer. Our hypothesis is that women who are ATM gene
carriers and who have received radiation therapy as part
of breast cancer treatment are at an increased risk of
developing a second primary breast cancer. We will also
provide descriptive statistics on the prevalence of ATM
in this large population-based sample of women.
Thereafter, we will determine the prevalence of BRCA1
and BRCA2 mutations in this population and evaluate
interactions between breast cancer, BRCA1/2 and
ATM genetic mutations, and radiation exposure.
Iowa contributed 111 cases and 235 controls to the
study population.
Lung Cancer Care Outcomes Research and
Surveillance Consortium
This study involves a coordinating center, the Iowa Cancer
Registry, and five other primary data collection and
research sites across the United States. Across these sites,
we are investigating patterns of care for lung cancer, the
reasons for particular care decisions by patients and their
physicians, variation in dissemination of modern care
8
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protocols and practices in different geographic areas,
and the effects of these decisions and practices on patient
outcomes, including quality of life. In Iowa, we plan to
rapidly identify and enroll 1,000 lung cancer patients
newly diagnosed over an 18-month period beginning
Spring 2003.
Epidemiological and Medical Monitoring Proposal of
Former Department of Defense Workers at The Iowa
Army Ammunitions Plant in Middletown, Iowa
This study aims to conduct an epidemiologic survey of
occupational health outcomes and needs for individuals
employed by the Department of Defense (DOD)
contractor, the Iowa Army Ammunition Plant in
Middletown, Iowa. The targeted employees worked in
conventional weapons manufacture on what was known
as Division A, which has been in operation from 1945
to the present. Historical exposure assessment and medical
surveillance data are being collected for these employees.
The data are also being linked to Iowa death tapes, Iowa
drivers’ licenses, Medicare files, and the Iowa Cancer
Registry incidence database.
Immunogenetic Determinants of Non-Hodgkin’s
Lymphoma (NHL) Survival
In this study we are collaborating with researchers at the
Mayo Clinic to investigate whether genes with functional,
common variant polymorphisms involved in immune
function and regulation are associated with overall survival
from NHL. The specific aims are to evaluate:
1) the association of polymorphisms in selected immune-
related genes from four key pathways on NHL survival
that include genes encoding inflammatory and regulatory
cytokines, Th1/Th2 cytokines, innate immunity, and
chemokines; 2) whether any effects are independent of
other established NHL prognostic factors (such as age and
stage) and treatment modalities; and 3) whether any effects
are specific to diffuse large B-cell lymphoma or the
combination of follicular and small lymphocytic
lymphoma. To achieve these aims, we are developing a
prognostic cohort from 364 HIV-negative NHL patients
who participated in the last few years in a population-based
case-control study in Iowa.
Second Cancer Studies of the Gastrointestinal System
The Second Cancer Studies of the GI System include
seven case-control investigations with a common primary
purpose of evaluating the relation between cancer treatment
(radiation and/or chemotherapy) and cancer risk for three
gastrointestinal organs (stomach, pancreas, esophagus).
Radiation and chemotherapy are commonly used as
treatment for the cancers in this series (Hodgkin’s disease
and cancer of the testis, breast  and cervix). Radiation and
chemotherapy may be given with the intention of curing
cancer or for cancer control and prolonged life.
The cumulative effect may include a risk of developing
treatment-induced cancers. The results of this series of
studies will help determine if current treatment protocols
should be modified to control the risk of second cancers
involving the stomach, pancreas, or esophagus.
A GIS Based Workbench to Interpret Cancer Maps
This research is developing and testing a methodology for
identifying regions of excess cancer burden for breast and
colorectal cancer in Iowa. It will refine measures of
geographic access to cancer prevention, treatment and
screening services in Iowa by computing values using fine-
scaled geographic data on individuals, the spatial choices
of individuals and the locations of service providers. It uses
State Health Registry of Iowa data for a ten-year period
and links patient files to Medicare and selected medical
insurance records. Statistical models are being computed
to associate specific cancer burden measures to predictor
variables that capture local characteristics of the area and
characteristics of the individuals. A regional simulation
workbench is being developed to generate the expected
range and variations in the cancer burden measures for
9
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small geographic areas of Iowa based on local demographic
characteristics of the area and statewide cancer burden
rates. Results can be used to plan more appropriate cancer
prevention and control programs.
Integrating Aging and Cancer Research
This is a 5-year planning and formulating grant that will
add a Cancer and Aging Program (CAP) to the research
activities of the Holden Comprehensive Cancer Center
(HCCC) at the University of Iowa. The CAP will be a
joint effort of the University of Iowa’s Center on Aging
and the HCCC. It will have three scientific aims:
1) biology of aging and cancer, 2) effects of co-morbidity
on clinical cancer outcomes, and 3) chemotherapy
pharmacology in older cancer patients. The Iowa Cancer
Registry incidence and follow-up databases will contribute
to aims 2 and 3. This grant will also provide for a pilot
grant program that will promote research in areas
selected by investigators involved with the development
of the CAP.
The Iowa and Missouri Combined Residential Radon
Epidemiologic Studies
The National Cancer Institute has funded a study that
combines Iowa and Missouri Residential Radon Lung
Cancer Studies. This combined study is building on
findings from previous research projects, including the
Iowa Radon Lung Cancer Study. The Iowa Radon Lung
Cancer Study demonstrated that prolonged exposure to
radon gas in the home is associated with increased lung
cancer risk and presents a significant environmental health
hazard. The combined study, which takes place from 2001
to 2005, seeks to determine the association between
residential radon progeny (decay products) exposure and
lung cancer. Since the radon progeny deliver the actual
radiation doses to lung tissues rather than the radon gas
itself, more accurate dose estimates can be obtained by
0
retrospectively determining exposure to the progeny.
The study uses a state-of-the-art retrospective radon
progeny detector that can estimate past radon progeny
concentrations by measuring decay products that have
been embedded in glass surfaces.  The study also explores
the shape of the dose-response curve that best describes
the relationship between residential radon progeny
exposure and lung cancer and evaluates whether exposure
to residential radon progeny is associated with specific
morphologic types of lung cancer, such as adenocarcinoma.
Cooperative Agreements and Other Registries
The SHRI maintains cooperative agreements with several
hospital cancer registries and other agencies. Some of these
include:
• Iowa Department of Public Health
• The University of Iowa
-Birth Defects Registry of Iowa
-Center for Health Effects of Environmental
 Contamination
-Injury Prevention Research Center
-Environmental Health Sciences Research Center
-Iowa Center for Agricultural Safety and Health
-Prevention Intervention Center
• Holden Comprehensive Cancer Center
• Center for Public Health Statistics
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